Management of pediatric hepatocellular carcinoma: A multimodal approach

Mira A. Kohorst, Deepti M. Warad, Jane M. Matsumoto, Julie K. Heimbach, Mounif El-Youssef, Carola A.S. Arndt, Vilmarie Rodriguez, Amulya A. Nageswara Rao

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

Original languageEnglish (US)
JournalPediatric Transplantation
DOIs
StateAccepted/In press - 2017

Fingerprint

Hepatocellular Carcinoma
Pediatrics
Transplants
Liver Transplantation
Doxorubicin
Cisplatin
Survival Rate
Recurrence
Drug Therapy
Survival
Liver
Therapeutics
Population
Neoplasms
sorafenib

Keywords

  • Chemoembolization
  • Hepatocellular carcinoma
  • Liver transplant
  • Pediatric
  • Sorafenib

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

Kohorst, M. A., Warad, D. M., Matsumoto, J. M., Heimbach, J. K., El-Youssef, M., Arndt, C. A. S., ... Nageswara Rao, A. A. (Accepted/In press). Management of pediatric hepatocellular carcinoma: A multimodal approach. Pediatric Transplantation. https://doi.org/10.1111/petr.13007

Management of pediatric hepatocellular carcinoma : A multimodal approach. / Kohorst, Mira A.; Warad, Deepti M.; Matsumoto, Jane M.; Heimbach, Julie K.; El-Youssef, Mounif; Arndt, Carola A.S.; Rodriguez, Vilmarie; Nageswara Rao, Amulya A.

In: Pediatric Transplantation, 2017.

Research output: Contribution to journalArticle

Kohorst, MA, Warad, DM, Matsumoto, JM, Heimbach, JK, El-Youssef, M, Arndt, CAS, Rodriguez, V & Nageswara Rao, AA 2017, 'Management of pediatric hepatocellular carcinoma: A multimodal approach', Pediatric Transplantation. https://doi.org/10.1111/petr.13007
Kohorst, Mira A. ; Warad, Deepti M. ; Matsumoto, Jane M. ; Heimbach, Julie K. ; El-Youssef, Mounif ; Arndt, Carola A.S. ; Rodriguez, Vilmarie ; Nageswara Rao, Amulya A. / Management of pediatric hepatocellular carcinoma : A multimodal approach. In: Pediatric Transplantation. 2017.
@article{7cca6e7cbb01495c8de7a96869263616,
title = "Management of pediatric hepatocellular carcinoma: A multimodal approach",
abstract = "HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.",
keywords = "Chemoembolization, Hepatocellular carcinoma, Liver transplant, Pediatric, Sorafenib",
author = "Kohorst, {Mira A.} and Warad, {Deepti M.} and Matsumoto, {Jane M.} and Heimbach, {Julie K.} and Mounif El-Youssef and Arndt, {Carola A.S.} and Vilmarie Rodriguez and {Nageswara Rao}, {Amulya A.}",
year = "2017",
doi = "10.1111/petr.13007",
language = "English (US)",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Management of pediatric hepatocellular carcinoma

T2 - A multimodal approach

AU - Kohorst, Mira A.

AU - Warad, Deepti M.

AU - Matsumoto, Jane M.

AU - Heimbach, Julie K.

AU - El-Youssef, Mounif

AU - Arndt, Carola A.S.

AU - Rodriguez, Vilmarie

AU - Nageswara Rao, Amulya A.

PY - 2017

Y1 - 2017

N2 - HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

AB - HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.

KW - Chemoembolization

KW - Hepatocellular carcinoma

KW - Liver transplant

KW - Pediatric

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85021186292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021186292&partnerID=8YFLogxK

U2 - 10.1111/petr.13007

DO - 10.1111/petr.13007

M3 - Article

C2 - 28631359

AN - SCOPUS:85021186292

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

ER -